课题基金 / 基金详情

Phase II Study PS341 Alone or Comb. w/ Irinotecan in Patients w/ Adenocarcinoma

Phase II Study PS341 Alone or Comb. w/ Irinotecan in Patients w/ Adenocarcinoma
II 期研究 PS341 单独或联合。
批准号：
7040643
负责人：
SCOTT H WADLER
金额：
$0.72万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
项目状态：
已结题
起止时间：
2004-04-01 至 2005-03-31
来源：
https://reporter.nih.gov/project-details/7040643
关键词：
adenocarcinomaantineoplasticsbiopsyclinical researchclinical trial phase IIcombination chemotherapydrug screening /evaluationesophagogastric junction disordergastrointestinal neoplasmsgene expressionhuman subjecthuman therapy evaluationirinotecanmicroarray technologyneoplasm /cancer chemotherapypatient oriented researchprotease inhibitorstomach neoplasms

项目成果

SCOTT H WADLER的其他基金

相似基金

相关文献

期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II STUDY BEVACIZUMAK, CETUXIMAB, IRINOTECAN IN COLORECTAL CANCER
PHASE II STUDY PS341 ALONE OR COMB W/ IRINOTECAN IN PATIENTS W/ ADENOCARCINOMA
A PHASE I/II STUDY OF GENASENSE (G3139) IN COMBINATION WITH CISPLATIN AND FLUORO
PHII TRIAPINE W/ GEMCITABINE ADENOCARCINOMA OF BILIARY DUCTS AND GALL BLADDER
海外基金